News for Greenwich LifeSciences, Inc. (GLSI)

STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. ( GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on

Greenwich LifeSciences, Inc. has a short cash runway, unclear market potential, and a high risk of trial failure. Learn more about GLSI stock here.

**media[527000]**

**media[524900]**

**media[522325]**

Greenwich LifeSciences (GLSI) stock gained after the company updated on commercial manufacturing of its lead candidate GP2. Read more here.

**media[521256]**

Greenwich LifeSciences initiates clinical sites in Germany with GBG partnership for FLAMINGO-01 study, targeting breast cancer research.

STAFFORD, Texas, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. ( GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on

On January 3, 2025, Snehal Patel, CEO and CFO, 10% Owner of Greenwich LifeSciences Inc (GLSI), purchased 3,400 shares of the company. Following this transaction

Although U.S. stocks closed lower on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the com...

The team at City Index have looked at some of the largest ever IPOs and ranked them by total revenue to find out which were the biggest ones of all time.

Read Investment Analysts’ Upgrades for May 30th (FERG, FMTX, FPAY, FXTGY, GBNH, GBOOY, GLSI, GORO, GRIN, GRPH) at ETF Daily News

Read Equities Research Analysts’ Updated EPS Estimates for April 21st (ADS, CBK, DG, ELA, ELMS, EMX, ENFN, ENLAY, ENLC, EVGO) at ETF Daily News

Here's a roundup of top developments in the biotech space over the last 24 hours: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs